If you or someone you know has Diabetes Type 2, call us today! We have research studies enrolling now.
No cost, and no health insurance is required to participate.
Ask your doctor or contact our clinic for more information.
For more information call:
Or sign up below!
- More Information about Diabetes
If diabetes is brought up to a member of the general public, they will usually be aware that the condition affects a person’s ability to regulate their blood sugar. However, they may not realize what is involved beyond checking blood sugars and possibly injecting insulin. On the other hand, most people that have been diagnosed with diabetes know that it is a very complex condition. Uncontrolled, high blood sugar affects everything from your head to your toes! If you have been diagnosed with diabetes, it is extremely important to manage and control your blood sugars. This will help minimize and prevent complications that arise from uncontrolled diabetes.
There is a common saying that “diabetes will not kill you, but its complication will.” Excess sugar in the blood causes damage to the small blood vessels and nerves. This in turn leads to damage to various diabetic complications including:
- Alzheimer’s Disease
- Diabetic nephropathy or kidney damage
- Diabetic neuropathy or nerve damage
- Diabetic ulcers
- Erectile dysfunction
Although there is not a cure for diabetes there are many effective avenues available to help manage and prevent the complications resulting from diabetes. ENCORE Research Group is working tirelessly to find new therapies for these conditions. If you would like to experience the science firsthand and help to move medicine forward, consider volunteering for a clinical trial!
This research study is enrolling at:
Jacksonville Center for Clinical Research
4085 University Blvd., South, Suite 1
Jacksonville, FL 32216
Read the latest posts by our expert clinical staff!
A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive Subjects
An Exploratory, Open-Label, Proof-of-Concept Study of Mavacamten (MYK-461) in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) and Chronic Elevation of Cardiac Troponin-I and/or NT-proBNP
- Jacksonville (All Sites)